Clinical trial · Observational
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
NCT06483425CI-TRIAL-00078498active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biomarker | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sequencing of DNA, RNA, and Proteins | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ovarian cancer pateitns
- description
- Patients diagnosed with Ovarian cancer in Tongji Hospital, Wuhan.
- interventionNames
- Genetic: Sequencing of DNA, RNA, and Proteins
Primary outcomes (1)
- measure
- Biomarker explorarion
- timeFrame
- 5 years
- description
- Blood, tumor, and other samples should be sequenced by RNA-seq, Next-Generation Sequencing, or proteomics to identify specific biomarkers associated with treatment response and prognosis in ovarian cancer.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with ovarian cancer. * Willingness to undergo biomarker testing. * Ability to provide informed consent for participation in the study. Exclusion Criteria: * Inability to comply with study requirements or follow-up visits. * Previous participation in a conflicting clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.